8-K - Turn Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Turn Therapeutics Inc. (Nasdaq: TTRX) announced the appointment of Dr. Robert Redfield, M.D., former CDC Director, as Senior Advisor of Health Policy and Regulatory Affairs to provide strategic guidance on GX-03, its lead investigational therapy in Phase 2 clinical trials for moderate-to-severe atopic dermatitis.

Key Takeaways

1Turn Therapeutics appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs on February 17, 2026.

2Dr. Redfield will guide clinical development, public health implications, and regulatory positioning of GX-03.

3GX-03 is a first-in-class, non-systemic topical inhibitor in Phase 2 clinical trials for atopic dermatitis.

4Dr. Redfield served as 18th Director of CDC from 2018 to 2021.

5Brad Burnam, CEO, stated Dr. Redfield's guidance will accelerate GX-03's regulatory path.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 17, 2026 104 Cover Page Interactive Data File (embedde

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE DATED FEBRUARY 17, 2026